SlideShare a Scribd company logo
Diagnostic Challenges In Uterine
Mesenchymal Tumors
Muneerah Saeed
MESENCHYMAL TUMORS OF THE UTERUS
Smooth muscle neoplasms
• Most common
• Majority- benign-
Leiomyoma
• MC-malignant-
Leiomyosarcoma; >50%
uterine sarcoma; 1-2%
uterine malignancy
Endometrial
stromal neoplasms
• 2nd most
common
Others
Mesenchymal tumors
Leiomyoma
 Cellular
 Leiomyoma with bizarre nuclei
 Mitotically active
 Hydropic
 Apoplectic
 Lipomatous (lipoleiomyoma)
 Epithelioid
 Myxoid
 Dissecting (cotyledonoid)
 Diffuse
 Intravenous
 Metastasizing
Smooth muscle tumor of uncertain
malignant potential
Leiomyosarcoma
 Epithelioid leiomyosarcoma
 Myxoid leiomyosarcoma
Endometrial stromal and related tumors
Endometrial stromal nodule
Low-grade endometrial stromal sarcoma
High-grade endometrial stromal sarcoma
Undifferentiated uterine sarcoma
Uterine tumor resembling ovarian sex cord Tumor
Miscellaneous mesenchymal tumors
Rhabdomyosarcoma
Perivascular epithelioid cell tumor
• Benign/Malignant
Others
Mixed epithelial and mesenchymal tumors
Adenomyoma
Atypical polypoid adenomyoma
Adenofibroma
Adenosarcoma
Carcinosarcoma
WHO(2014) Classification Of Tumors Of The Uterine Corpus
GROSS EXAMINATION
 Macroscopic examination of mesenchymal tumors cannot be overemphasized
 Typical fibroids, up to 3 of the largest tumors- hysterectomies and every fragment- myomectomy
specimens
 Diligent sampling- Deviations from usual gross appearance
 “Degenerative” changes
 Variant
 Malignancy
 Exogenous hormonal preparations
 Sections of the tumor/myometrial interface- most rewarding- diagnostically challenging
tumors- irregular, infiltrative border/ vascular invasion identified
 Multiple appropriately sampled sections are all that is frequently required in problematic
cases to enable a definitive diagnosis to be made.
GROSS PATHOLOGICAL FEATURES LEIOMYOMA COMPARED WITH LEIOMYOSARCOMA
Hydropic features centrally with microcyst
formation, characteristic- Ulipristal acetateYellow cut surface of lipoleiomyoma
Cellular leiomyoma- yellow cut surface
Endometrial stromal nodule: neoplastic stroma-
distinctive yellow appearance + smooth muscle
differentiation- tan areas
• Yellow
• Lack characteristic
whorled bulging
appearance
-Cellular leiomyoma:
Myometrium
-ESN: Softer,
endometrium
Endometrial stromal sarcoma,
low-grade- intracavitary polypoid
mass - numerous soft yellow tan
nodules
Endometrial stromal sarcoma,
high grade- polypoid intracavitary
mass- extensive hemorrhage
Undifferentiated uterine
sarcoma
Endometrial stromal tumors
Endometrial
stromal nodule
Low-grade endometrial
stromal sarcoma
High-grade endometrial
stromal sarcoma
Undifferentiated uterine
sarcoma
Uterine tumor resembling
ovarian sex cord Tumor
Endometrial Stromal Nodule
 Characterized by sharp circumscription between the neoplastic cells and surrounding endometrium
or myometrium, with a pushing interface
 Sometimes, finger-like extensions into surrounding myometrium, but these foci should be <3 in
number & < 3 mm from the main mass; otherwise low grade ESS
 No lymphatic or vascular invasion is present
 Resembles proliferative phase endometrial stroma
 These cells appear to whorl around the prominent vascular component, which resembles the spiral
arterioles of non-neoplastic endometrium
 Foamy stromal cells may be conspicuous
Foamy cells are a characteristic
characteristic cytomorphology and
vasculature
well-demarcated border with the
myometrium
Endometrial Stromal Nodule
Low-Grade Endometrial Stromal Sarcoma
 Women with low-grade ESS are typically perimenopausal but tend to be younger
than those who present with other types of uterine sarcoma
 Histologically, low-grade ESS cells morphologically indistinguishable from ESN
 Generally low mitotic rate & necrosis uncommon
 ESN and low-grade ESS, can occasionally exhibit a diverse range of differentiation
including sex cord–like, epithelial (e.g., endometrioid type glands), smooth
muscle, and, rarely, skeletal muscle differentiation
Endometrial stromal sarcoma, low
grade. Shown is vascular invasion
Mixed endometrial stromal–smooth
muscle tumor. An area of smooth muscle
differentiation
Endometrial stromal sarcoma, low
grade. Ovarian sex cord–like
Prominent endometrioid glandular
differentiation
Ddx-Highly cellular leiomyoma
High-Grade Endometrial Stromal Sarcoma
 Histologically, the tumor shows extensive finger-like permeation of the myometrium and
lymphovascular invasasion
 The tumor typically contains morphologically low- and high-grade areas
biphasic growth-morphologically
low-grade & high-grade
component
Morphologically low-grade areas
have a similar appearance to
fibromyxoid variant of a low-grade
ESS
high-grade areas, tumor cells appear
epithelioid, with more vesicular
nuclei, mitotic activity and
karyorrhexis.
High-Grade Endometrial Stromal Sarcoma
Undifferentiated Uterine Sarcoma
 Neoplastic cells show marked cellular atypia and numerous mitoses, including atypical
forms, without evidence of differentiation toward endometrial stroma both
cytomorphologically
 Diffuse and destructive infiltrative pattern as opposed to the characteristic
wormlike pattern and propensity for intravascular extension characteristic of
low-grade ESS
 Differential diagnosis: poorly differentiated carcinoma, leiomyosarcoma, and
carcinosarcoma, all of which may be morphologically similar in appearance
Undifferentiated Uterine Sarcoma
Undifferentiated uterine sarcoma. A pleomorphic sarcoma
with numerous, often atypical, mitoses
Immunohistochemistry In Endometrial Stromal Tumors
 Frequently positive for cd10, ER, PR. High grade endometrial stromal sarcoma with t(10;17) and
undifferentiated endometrial sarcomas, are ER and PR negative
 Can be positive for actin and keratin
 Desmin and h-caldesmon are generally negative. But are typically positive in areas showing smooth-
muscle differentiation and often positive in areas of sex cord-like differentiation.
Marker LG-ESS HG-ESS UUS LM/LMS
CD10 ++ +/- Patchy +/-
Desmin +/- +/- ++
H-caldesmon +/- +/- ++
ER ++ +/- Patchy +/-
PR ++ +/- Patchy +/-
Cyclin D1 - ++ +/-
CD117 +
UTERINE SMOOTH MUSCLE TUMORS
Leiomyoma(benign)
 Cellular (highly) LM
 LM with bizarre nuclei
 Mitotically active LM
 Myxoid LM
 Hydropic LM
 LM with heterologous elements
(lipoLM)
Leiomyosarcoma
(50% 5-year survival)
• Epithelioid LMS
• Myxoid LMS
STUMP
Intravascular Leiomyomatosis
Diffuse peritoneal Leiomyomatosis
Benign metastasizing LMUterine
DIAGNOSTIC CHALLENGES IN UTERINE SMOOTH MUSCLE TUMORS
TYPICAL LEIOMYOMA
- Not problematic
 Variable amounts of collagenous tissue-
initially in between smooth muscle
cells; later replacing smooth muscle
cells.
 Extensive hyalinization- difficult to
recognize- as a smooth muscle
neoplasm. Usually postmenopausal-
both dystrophic calcification and
ossification.
LEIOMYOSARCOMA
The 3 principal factors in the determination of malignancy:
 Obvious proliferative activity- Increased mitotic figures
 Significant nuclear and cytologic atypia
 Cellular instability- particular pattern of necrosis.
In addition, these tumors may be hypercellular and infiltrate into
surrounding myometrium.
Evaluation of Mitotic Activity
 Typically, Mitotic figures counted in adjacent high-power fields(Recommended ≥30) and
averaged over 10 hpf. Note mitotic rate of proliferative hot spots when found.
 Diagnostic pitfall: Care must be taken that the mitoses are not counted adjacent to a zone of
ulceration and regeneration. This pitfall is usually seen in a benign submucosal leiomyoma
exposed to traumatic injury
 Most important prognostic factor identified histologically. Use of Ki-67 antigen, IHC surrogate
for counting mitotic figures, is far less clear. Another proliferation marker, phosphorylated
histone H3; produces counts comparable to the H&E gold standard for leiomyoma but tends to
inflate counts for leiomyosarcoma.
 Each potential mitotic figure must be carefully scrutinized to ensure that it is not a
degenerating cell.
 Such mimics, with pyknotic nuclei are common in benign and malignant tumors
 Casual counting may drastically overestimate proliferation in a given tumor
Diagnostic challenges in uterine mesenchymal tumors
Evaluation of Cytologic Atypia
 Significant(Moderate or Severe) nuclear atypia- the atypia should be notable at low (10× objective)
power
 The degree of nuclear atypia found in leiomyosarcomas spans a wide spectrum: pleomorphic tumor
cells also may resemble trophoblastic malignancy, inflammatory giant cells or osteoclasts
 May also be manifested in leiomyosarcoma by divergent (heterologous) patterns of differentiation,
which may include osteosarcomatous, rhabdomyosarcomatous, and chondrosarcomatous foci
Leiomyosarcoma with extreme nuclear
atypia resembling malignant
trophoblasts
Osteosarcomatous differentiation in
leiomyosarcoma
Atypical giant cells in a
leiomyosarcoma
Evaluation of Tumor Cell Necrosis
• Of the three principal factors, tumor necrosis
carry the greatest weight in the determination
of malignancy
• Malignancy-associated tumor necrosis has
to be carefully distinguished from benign
degenerative changes and other
therapeutic effects.
• Difficult to classify - subjective as well as
degenerative processes need not be limited to
benign tumors, and mixed patterns of necrosis
in a malignant tumor may be confusing
Infarct type necrosis: poorly demarcated zone between the viable tumor cells and central degenerative area, with
hyalinization and hemorrhage
Geographic tumor cell necrosis: Sharp line of demarcation of island like zone of tumor & Atypical ghost cell
DIFFERENTIAL DIAGNOSIS OF LEIOMYOSARCOMA
 Leiomyoma with infarction
 Mitotically active leiomyoma
 Leiomyoma with bizarre nuclei
 Smooth Muscle tumor of Uncertain Malignant Potential(STUMP)
 High grade Stromal sarcoma
Ddx- Mitotically Active Leiomyoma
Mitotically active leiomyoma LMS
Grossly appear same as usual leiomyoma. Smaller and well
circumscribed
Variegated appearance with areas of necrosis and
hemorrhage. large
Women younger than 35 years Older women
Most cases asso. with secretory endometrium -suggesting
increased mitotic activity- progesterone related effect. Use of
exogenous progestogens- implicated as a cause of increased
proliferation.
No such association
Mitotic activity 5-14/10HPF Mitotic activity ≥ 10/ 10HPF
No necrosis or atypia(focal bizarre nuclei may be seen) Necrosis and/or atypia present
Ddx- Leiomyoma With Bizarre Nuclei
 Presence of ≥ 5% multinucleated, multilobated or mononucleated bizarre giant nuclei with prominent
smudged and clumped nuclear chromatin. Intranuclear eosinophilic cytoplasmic pseudo-inclusions
seen within the bizarre nuclei.
 Reactive to p16 (86.5%) & p53(60%). Nearly half show over 10% positive for Ki-67. Therefore; these
have a limited role in distinguishing these two tumors
LBN LMS
Bizarre cells distributed either focally or multifocally lying
in a background of smooth muscle cells of usual type
background cells are usually all cytologically atypical
when scrutinized at high power magnification
Hypercellular Hypercellular
No increase in mitosis. Degenerative changes seen within
atypical nuclei. Karyorrhectic nuclei seen
Increased mitosis seen
Infarct type necrosis may be seen Tumor necrosis seen
Leiomyoma with bizarre nuclei
Leiomyosarcoma, background cells all pleomorphic
with
multinucleated bizarre cells with several mitotic
figures
FH- Deficient Leiomyoma
 Leiomyomata associated with a mutation of Fumarate hydratase (FH)- overlapping
features with leiomyoma with bizarre nuclei
 seen in younger women <40 years of age as multiple leiomyomata
 Mostly sporadic- may carry a germline mutation of FH associated with the HLRCC
(hereditary leiomyomatosis and renal cell carcinoma syndrome)
 . FH & S-(2-succino)-cysteine (2SC) can be detected immunohistochemically
Show increased cellularity, staghorn vessels, neurilemmoma-like nuclear palisading and
prominent inclusion-like eosinophilic macronucleoli with a perinuclear halo. Nuclear
atypia and multinucleation
Neurilemmoma like areas of nuclear palisading
FH deficient leiomyoma with perinuclear haloes
and eosinophilic inclusions
Ddx- Smooth Muscle tumor of Uncertain Malignant Potential
(STUMP)
• Few tumors have phenotypic features between the benign variants and the
leiomyosarcomas.
• When the problem of classifying tumors with intermediate morphologic features
was appreciated, a new diagnostic category was introduced—STUMP
Epithelioid Leiomyosarcoma
 Rounded, nonspindled tumor cells with abundant eosinophilic cytoplasm
 May have reduced expression of smooth muscle markers (e.g., desmin, h-caldesmon). application
of another marker of smooth muscle differentiation, histone deacetylase 8 (HDAC8), may be helpful
Epithelioid Leiomyosarcoma Epithelioid Leiomyoma
Epithelioid Leiomyosarcoma
Differential Diagnosis of Epithelioid Leiomyosarcoma
 Epithelioid leiomyoma
 Epithelioid ESS
 Perivascular Epithelioid Cell Tumor (PEComa)
 Other Sarcomas with epithelioid/ rhabdoid morphology
Ddx- Perivascular Epithelioid Cell Tumor (PEComa)
 These are rare mesenchymal tumors of the FGT, MC- affecting the uterus
 Characteristically they co-express melanocytic and muscle markers
 Important to dx- respond to mTOR inhibitor therapy
 Characterised predominantly by epithelioid, clear cell morphology and without pleomorphism
and an IHC
 positivity: HMB45, TFE3 and cathepsin K
 negativity for MiTF, SMA and desmin
(a) PEComa cords of cells with clear cytoplasm. (b) PEComa with
immunopositivity for HMB45. (c) PEComa showing positive
immmunoreactivity for TFE3
Myxoid Leiomyosarcoma
 Rare variant of uterine leiomyosarcoma
 The increased extracellular matrix reduces cellularity and consequently counts of mitotic activity.
 Myxoid leiomyosarcoma diagnosed with any one of the following features:
(1) more than 2 mitoses/10 hpf; (2) significant cytologic atypia;
(3) tumor cell necrosis; and (4) destructive infiltration of adjacent myometrium
Myxoid Leiomyosarcoma
Infiltrating tumor cells permeating through myometrial
fascicles
loose collection of atypical cells and an occasional
mitotic figure (center and inset) in a rarified stroma.
Differential diagnosis of Myxoid Leiomyosarcoma
 Inflammatory Myofibroblastic Tumor (IMT)
 Hydropic leiomyoma
 Myxoid ESS
Ddx- Inflammatory Myofibroblastic Tumor (IMT)
 mesenchymal tumor of low malignant potential. It shows a
cellular proliferation of spindled to epithelioid cells in a myxoid
stromal background.
 a conspicuous lymphoplasmacytic infiltrate within the neoplasm
 Absence of IHC anaplastic lymphoma kinase (ALK) staining or
ALK gene rearrangement by FISH
IMT Myxoid leiomyosarcoma
No evidence of aberrant
immunoreactivity with p53
50% showed aberrant expression of p53,
the most common being a “null” pattern
Patchy, heterogenous reactivity with P16. Abnormal P16 (strong and diffuse)
observed in 70%
Inflammatory myofibroblastic tumor:
myxoid stromal background
Ddx- Hydropic leiomyoma
• Grossly, the wet, slippery, cut surface can be described as “myxoid”. Histologically
examined to exclude a myxoid leiomyosarcoma by recognizing their edematous
nature and lack of other malignant features
• Hydropic degeneration may be worrisome at lower magnifications- irregular contours
and sharper borders
• Careful attention at higher magnifications often resolves this by noting the fluid-filled
intercellular spaces and the absence of truly necrotic cells.
Immunohistochemistry in Smooth muscle tumor
Marker Leiomyoma Leiomyosarcoma
Desmin; h-caldesmon; smooth
muscle actin
histone deacetylase 8 (HDCA8)
Positive; h- caldesmon- m.spec
Epithelioid variant: -ve or focally
reactive
usually express; epithelioid and
myxoid leiomyosarcomas may show
lesser degrees of immunoreaction
oxytocin receptor, estrogen receptor
(ER), progesterone receptor(PR), and
WT1
Often positive; Oxytocin receptor
helps to distinguish a smooth muscle
tumor (positive) from an endometrial
stromal tumor (negative)
ER, PR, and AR in 30-40% of cases
CD10,9 cytokeratins and EMA CD10 in 40% of cellular leiomyomas often immunoreactive(EMA most
frequently positive in the epithelioid
variant)
P16; p53; Ki67 Ki67 lower; no overexpression p53&
p16 except LBN
Ki67 higher; overexpression of
p53(25-47%) and p16
Mixed epithelial and mesenchymal tumors
 Adenomyoma
 Atypical polypoid adenomyoma
 Adenofibroma
 Adenosarcoma
 Carcinosarcoma
Mixed epithelial and mesenchymal tumors
Atypical polypoid adenomyoma. Shown is
an admixture of fibromyomatous stroma with
endometrial-type glands
Adenosarcoma. Note the phyllodes-like glandular growth
pattern, with prominent hypercellular stroma cuffing the glands.
HP: stromal cellular atypia
Mixed epithelial and mesenchymal tumors
Carcinosarcoma. Note the sharply demarcated
sarcomatous
region with malignant cartilage (bottom) contrasting
with the
THANKYOU
REFFERANCES
 2014 WHO Tumors of the female genital tract
 Blaustein’s Pathology pf the female genital tract; 7th edition
 Problematic areas and new developments in uterine mesenchymal tumors; Nafisa Wilkinson &
Nicholas R Griffin; diag histopath; 2017
 Diagnostic use of immunohistochemistry in uterine mesenchymal tumors; Emanuela et al;
seminars in diag path; 2014
 Recent developments in uterine mesenchymal neoplasms; Sarah Chiang & Esther Oliva; histopath;
2013
REFFERANCES
 Uterine mesenchymal tumors; Nikhil A. Sangle, Subodh M. Lele1; IJPM; 2011
 Malignant mesenchymal tumors of the uterus - time to advocate a genetic classification;
Birgit et al; Expert Review of Anticancer Therapy; 2016

More Related Content

PPT
Healing and repair
PPT
Uterine sarcoma
PPTX
Molecular Genetics and Recent updates of Soft tissue tumours Dr.Argha Baruah
PPTX
Pre malignant lesions of skin
PDF
Schizophrenia case presentation.
PPTX
fluid and electrolyte disturbance in human body
PPT
Psychiatry history taking
Healing and repair
Uterine sarcoma
Molecular Genetics and Recent updates of Soft tissue tumours Dr.Argha Baruah
Pre malignant lesions of skin
Schizophrenia case presentation.
fluid and electrolyte disturbance in human body
Psychiatry history taking

What's hot (20)

PPTX
Immunohistochemistry in Gynaecological Cancers
PPTX
Molecular subtypes of breast cancer
PPTX
IHC in breast pathology
PPTX
High Grade Papillary Serous Cystadenocarcinoma of Bilateral Ovaries with Caps...
PPTX
Prognostic factors in carcinoma breast ppt
PPTX
Pathology of breast cancer
PPTX
paris presentation.pptx
PDF
Breast pathology 1
PPTX
Molecular profiling of breast cancer
PPTX
Whipple's specimen grossing
PPTX
Grossing colon.pptx
PPTX
Germ cell tumors of ovary
PPT
Small round cell_tumor_DR NARMADA
PPTX
Recent updates and reporting of testicular tumors Dr.Argha Baruah
PDF
PPTX
papillary lesions of the breast.pptx
PPT
Pathology of Breast Disorders
PPTX
gastrointestinal Neuro endocrine tumors , GIT NET
PPTX
GLEASON SCORING . Dr. Abhinav Golla , Associate Professor , Lab Director & C...
PPTX
Breast Pathology Lecture - 2013
Immunohistochemistry in Gynaecological Cancers
Molecular subtypes of breast cancer
IHC in breast pathology
High Grade Papillary Serous Cystadenocarcinoma of Bilateral Ovaries with Caps...
Prognostic factors in carcinoma breast ppt
Pathology of breast cancer
paris presentation.pptx
Breast pathology 1
Molecular profiling of breast cancer
Whipple's specimen grossing
Grossing colon.pptx
Germ cell tumors of ovary
Small round cell_tumor_DR NARMADA
Recent updates and reporting of testicular tumors Dr.Argha Baruah
papillary lesions of the breast.pptx
Pathology of Breast Disorders
gastrointestinal Neuro endocrine tumors , GIT NET
GLEASON SCORING . Dr. Abhinav Golla , Associate Professor , Lab Director & C...
Breast Pathology Lecture - 2013
Ad

Similar to Diagnostic challenges in uterine mesenchymal tumors (20)

PPTX
Presentation1 NEOPLASIA III II YEAR UNDER - Copy_2.pptx
PDF
neoplasia-120107095645-phpapp01 2.pdf
PPTX
Neoplasia - Patholgy
PPT
Soft tissue sarcoma
PPT
Soft tissue sarcoma
PPTX
Neoplasia class 1.pptx
PPTX
PPT
Neoplasia 2
PPTX
Neoplasia part 1
PPTX
Pitfalls in diagnosis of soft tissue tumors of childhood
PDF
Neoplasia - Benign and malignant tumours nomenclature and difference.pdf
PPT
Ovarian tumors
PPTX
Neoplasia
PPTX
ovarian tumors.pptx
PPT
Approch to Mesenchymal tumors of the Uterus
PPTX
OVARIAN TUMOURS
PPTX
Neoplasia: Nomenclature, Staging and Grading
PPTX
Neoplasia &amp; carcinogenesis.pptx dr.jawahar singh.pptx 1
PDF
Neoplasm - basic of oncology
Presentation1 NEOPLASIA III II YEAR UNDER - Copy_2.pptx
neoplasia-120107095645-phpapp01 2.pdf
Neoplasia - Patholgy
Soft tissue sarcoma
Soft tissue sarcoma
Neoplasia class 1.pptx
Neoplasia 2
Neoplasia part 1
Pitfalls in diagnosis of soft tissue tumors of childhood
Neoplasia - Benign and malignant tumours nomenclature and difference.pdf
Ovarian tumors
Neoplasia
ovarian tumors.pptx
Approch to Mesenchymal tumors of the Uterus
OVARIAN TUMOURS
Neoplasia: Nomenclature, Staging and Grading
Neoplasia &amp; carcinogenesis.pptx dr.jawahar singh.pptx 1
Neoplasm - basic of oncology
Ad

Recently uploaded (20)

PPTX
Fundamentals of human energy transfer .pptx
PDF
Writing and Teaching as Personal Documentation of Continuing Professional Dev...
PPTX
Drug hypersensitivity Prof Ghada Shousha, Assistant Professor of pediatrics, ...
PPTX
Respiratory drugs, drugs acting on the respi system
PDF
july 2025 DERMATOLOGY diseases atlas with hyperlink.pdf
PPTX
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
PPTX
Note on Abortion.pptx for the student note
PDF
Medical Evidence in the Criminal Justice Delivery System in.pdf
PDF
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
PPTX
Nirsevimab in India - Single-Dose Monoclonal Antibody to Combat RSV .pptx
PPTX
Uterus anatomy embryology, and clinical aspects
DOCX
Pathology Paper II – II MBBS Main Exam (July 2025) | New CBME Scheme
PPTX
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
PPTX
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
PPTX
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
PPTX
Thyroid Applied Anatomy, Pysiology, Development with MCQs.pptx
DOCX
RUHS II MBBS Pathology Paper-I with Answer Key | 30 July 2025 (New Scheme)
PPTX
ACID BASE management, base deficit correction
PPTX
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
PPTX
Gastroschisis- Clinical Overview 18112311
Fundamentals of human energy transfer .pptx
Writing and Teaching as Personal Documentation of Continuing Professional Dev...
Drug hypersensitivity Prof Ghada Shousha, Assistant Professor of pediatrics, ...
Respiratory drugs, drugs acting on the respi system
july 2025 DERMATOLOGY diseases atlas with hyperlink.pdf
CEREBROVASCULAR DISORDER.POWERPOINT PRESENTATIONx
Note on Abortion.pptx for the student note
Medical Evidence in the Criminal Justice Delivery System in.pdf
Therapeutic Potential of Citrus Flavonoids in Metabolic Inflammation and Ins...
Nirsevimab in India - Single-Dose Monoclonal Antibody to Combat RSV .pptx
Uterus anatomy embryology, and clinical aspects
Pathology Paper II – II MBBS Main Exam (July 2025) | New CBME Scheme
15.MENINGITIS AND ENCEPHALITIS-elias.pptx
NEET PG 2025: Memory-Based Recall Questions Compiled by Dr. Shivankan Kakkar, MD
POLYCYSTIC OVARIAN SYNDROME.pptx by Dr( med) Charles Amoateng
Thyroid Applied Anatomy, Pysiology, Development with MCQs.pptx
RUHS II MBBS Pathology Paper-I with Answer Key | 30 July 2025 (New Scheme)
ACID BASE management, base deficit correction
ca esophagus molecula biology detailaed molecular biology of tumors of esophagus
Gastroschisis- Clinical Overview 18112311

Diagnostic challenges in uterine mesenchymal tumors

  • 1. Diagnostic Challenges In Uterine Mesenchymal Tumors Muneerah Saeed
  • 2. MESENCHYMAL TUMORS OF THE UTERUS Smooth muscle neoplasms • Most common • Majority- benign- Leiomyoma • MC-malignant- Leiomyosarcoma; >50% uterine sarcoma; 1-2% uterine malignancy Endometrial stromal neoplasms • 2nd most common Others
  • 3. Mesenchymal tumors Leiomyoma  Cellular  Leiomyoma with bizarre nuclei  Mitotically active  Hydropic  Apoplectic  Lipomatous (lipoleiomyoma)  Epithelioid  Myxoid  Dissecting (cotyledonoid)  Diffuse  Intravenous  Metastasizing Smooth muscle tumor of uncertain malignant potential Leiomyosarcoma  Epithelioid leiomyosarcoma  Myxoid leiomyosarcoma Endometrial stromal and related tumors Endometrial stromal nodule Low-grade endometrial stromal sarcoma High-grade endometrial stromal sarcoma Undifferentiated uterine sarcoma Uterine tumor resembling ovarian sex cord Tumor Miscellaneous mesenchymal tumors Rhabdomyosarcoma Perivascular epithelioid cell tumor • Benign/Malignant Others Mixed epithelial and mesenchymal tumors Adenomyoma Atypical polypoid adenomyoma Adenofibroma Adenosarcoma Carcinosarcoma WHO(2014) Classification Of Tumors Of The Uterine Corpus
  • 4. GROSS EXAMINATION  Macroscopic examination of mesenchymal tumors cannot be overemphasized  Typical fibroids, up to 3 of the largest tumors- hysterectomies and every fragment- myomectomy specimens  Diligent sampling- Deviations from usual gross appearance  “Degenerative” changes  Variant  Malignancy  Exogenous hormonal preparations  Sections of the tumor/myometrial interface- most rewarding- diagnostically challenging tumors- irregular, infiltrative border/ vascular invasion identified  Multiple appropriately sampled sections are all that is frequently required in problematic cases to enable a definitive diagnosis to be made.
  • 5. GROSS PATHOLOGICAL FEATURES LEIOMYOMA COMPARED WITH LEIOMYOSARCOMA
  • 6. Hydropic features centrally with microcyst formation, characteristic- Ulipristal acetateYellow cut surface of lipoleiomyoma
  • 7. Cellular leiomyoma- yellow cut surface Endometrial stromal nodule: neoplastic stroma- distinctive yellow appearance + smooth muscle differentiation- tan areas • Yellow • Lack characteristic whorled bulging appearance -Cellular leiomyoma: Myometrium -ESN: Softer, endometrium
  • 8. Endometrial stromal sarcoma, low-grade- intracavitary polypoid mass - numerous soft yellow tan nodules Endometrial stromal sarcoma, high grade- polypoid intracavitary mass- extensive hemorrhage Undifferentiated uterine sarcoma
  • 9. Endometrial stromal tumors Endometrial stromal nodule Low-grade endometrial stromal sarcoma High-grade endometrial stromal sarcoma Undifferentiated uterine sarcoma Uterine tumor resembling ovarian sex cord Tumor
  • 10. Endometrial Stromal Nodule  Characterized by sharp circumscription between the neoplastic cells and surrounding endometrium or myometrium, with a pushing interface  Sometimes, finger-like extensions into surrounding myometrium, but these foci should be <3 in number & < 3 mm from the main mass; otherwise low grade ESS  No lymphatic or vascular invasion is present  Resembles proliferative phase endometrial stroma  These cells appear to whorl around the prominent vascular component, which resembles the spiral arterioles of non-neoplastic endometrium  Foamy stromal cells may be conspicuous
  • 11. Foamy cells are a characteristic characteristic cytomorphology and vasculature well-demarcated border with the myometrium Endometrial Stromal Nodule
  • 12. Low-Grade Endometrial Stromal Sarcoma  Women with low-grade ESS are typically perimenopausal but tend to be younger than those who present with other types of uterine sarcoma  Histologically, low-grade ESS cells morphologically indistinguishable from ESN  Generally low mitotic rate & necrosis uncommon  ESN and low-grade ESS, can occasionally exhibit a diverse range of differentiation including sex cord–like, epithelial (e.g., endometrioid type glands), smooth muscle, and, rarely, skeletal muscle differentiation
  • 13. Endometrial stromal sarcoma, low grade. Shown is vascular invasion Mixed endometrial stromal–smooth muscle tumor. An area of smooth muscle differentiation Endometrial stromal sarcoma, low grade. Ovarian sex cord–like Prominent endometrioid glandular differentiation
  • 15. High-Grade Endometrial Stromal Sarcoma  Histologically, the tumor shows extensive finger-like permeation of the myometrium and lymphovascular invasasion  The tumor typically contains morphologically low- and high-grade areas
  • 16. biphasic growth-morphologically low-grade & high-grade component Morphologically low-grade areas have a similar appearance to fibromyxoid variant of a low-grade ESS high-grade areas, tumor cells appear epithelioid, with more vesicular nuclei, mitotic activity and karyorrhexis. High-Grade Endometrial Stromal Sarcoma
  • 17. Undifferentiated Uterine Sarcoma  Neoplastic cells show marked cellular atypia and numerous mitoses, including atypical forms, without evidence of differentiation toward endometrial stroma both cytomorphologically  Diffuse and destructive infiltrative pattern as opposed to the characteristic wormlike pattern and propensity for intravascular extension characteristic of low-grade ESS  Differential diagnosis: poorly differentiated carcinoma, leiomyosarcoma, and carcinosarcoma, all of which may be morphologically similar in appearance
  • 18. Undifferentiated Uterine Sarcoma Undifferentiated uterine sarcoma. A pleomorphic sarcoma with numerous, often atypical, mitoses
  • 19. Immunohistochemistry In Endometrial Stromal Tumors  Frequently positive for cd10, ER, PR. High grade endometrial stromal sarcoma with t(10;17) and undifferentiated endometrial sarcomas, are ER and PR negative  Can be positive for actin and keratin  Desmin and h-caldesmon are generally negative. But are typically positive in areas showing smooth- muscle differentiation and often positive in areas of sex cord-like differentiation. Marker LG-ESS HG-ESS UUS LM/LMS CD10 ++ +/- Patchy +/- Desmin +/- +/- ++ H-caldesmon +/- +/- ++ ER ++ +/- Patchy +/- PR ++ +/- Patchy +/- Cyclin D1 - ++ +/- CD117 +
  • 20. UTERINE SMOOTH MUSCLE TUMORS Leiomyoma(benign)  Cellular (highly) LM  LM with bizarre nuclei  Mitotically active LM  Myxoid LM  Hydropic LM  LM with heterologous elements (lipoLM) Leiomyosarcoma (50% 5-year survival) • Epithelioid LMS • Myxoid LMS STUMP Intravascular Leiomyomatosis Diffuse peritoneal Leiomyomatosis Benign metastasizing LMUterine
  • 21. DIAGNOSTIC CHALLENGES IN UTERINE SMOOTH MUSCLE TUMORS TYPICAL LEIOMYOMA - Not problematic  Variable amounts of collagenous tissue- initially in between smooth muscle cells; later replacing smooth muscle cells.  Extensive hyalinization- difficult to recognize- as a smooth muscle neoplasm. Usually postmenopausal- both dystrophic calcification and ossification.
  • 22. LEIOMYOSARCOMA The 3 principal factors in the determination of malignancy:  Obvious proliferative activity- Increased mitotic figures  Significant nuclear and cytologic atypia  Cellular instability- particular pattern of necrosis. In addition, these tumors may be hypercellular and infiltrate into surrounding myometrium.
  • 23. Evaluation of Mitotic Activity  Typically, Mitotic figures counted in adjacent high-power fields(Recommended ≥30) and averaged over 10 hpf. Note mitotic rate of proliferative hot spots when found.  Diagnostic pitfall: Care must be taken that the mitoses are not counted adjacent to a zone of ulceration and regeneration. This pitfall is usually seen in a benign submucosal leiomyoma exposed to traumatic injury  Most important prognostic factor identified histologically. Use of Ki-67 antigen, IHC surrogate for counting mitotic figures, is far less clear. Another proliferation marker, phosphorylated histone H3; produces counts comparable to the H&E gold standard for leiomyoma but tends to inflate counts for leiomyosarcoma.
  • 24.  Each potential mitotic figure must be carefully scrutinized to ensure that it is not a degenerating cell.  Such mimics, with pyknotic nuclei are common in benign and malignant tumors  Casual counting may drastically overestimate proliferation in a given tumor
  • 26. Evaluation of Cytologic Atypia  Significant(Moderate or Severe) nuclear atypia- the atypia should be notable at low (10× objective) power  The degree of nuclear atypia found in leiomyosarcomas spans a wide spectrum: pleomorphic tumor cells also may resemble trophoblastic malignancy, inflammatory giant cells or osteoclasts  May also be manifested in leiomyosarcoma by divergent (heterologous) patterns of differentiation, which may include osteosarcomatous, rhabdomyosarcomatous, and chondrosarcomatous foci
  • 27. Leiomyosarcoma with extreme nuclear atypia resembling malignant trophoblasts Osteosarcomatous differentiation in leiomyosarcoma Atypical giant cells in a leiomyosarcoma
  • 28. Evaluation of Tumor Cell Necrosis • Of the three principal factors, tumor necrosis carry the greatest weight in the determination of malignancy • Malignancy-associated tumor necrosis has to be carefully distinguished from benign degenerative changes and other therapeutic effects. • Difficult to classify - subjective as well as degenerative processes need not be limited to benign tumors, and mixed patterns of necrosis in a malignant tumor may be confusing
  • 29. Infarct type necrosis: poorly demarcated zone between the viable tumor cells and central degenerative area, with hyalinization and hemorrhage Geographic tumor cell necrosis: Sharp line of demarcation of island like zone of tumor & Atypical ghost cell
  • 30. DIFFERENTIAL DIAGNOSIS OF LEIOMYOSARCOMA  Leiomyoma with infarction  Mitotically active leiomyoma  Leiomyoma with bizarre nuclei  Smooth Muscle tumor of Uncertain Malignant Potential(STUMP)  High grade Stromal sarcoma
  • 31. Ddx- Mitotically Active Leiomyoma Mitotically active leiomyoma LMS Grossly appear same as usual leiomyoma. Smaller and well circumscribed Variegated appearance with areas of necrosis and hemorrhage. large Women younger than 35 years Older women Most cases asso. with secretory endometrium -suggesting increased mitotic activity- progesterone related effect. Use of exogenous progestogens- implicated as a cause of increased proliferation. No such association Mitotic activity 5-14/10HPF Mitotic activity ≥ 10/ 10HPF No necrosis or atypia(focal bizarre nuclei may be seen) Necrosis and/or atypia present
  • 32. Ddx- Leiomyoma With Bizarre Nuclei  Presence of ≥ 5% multinucleated, multilobated or mononucleated bizarre giant nuclei with prominent smudged and clumped nuclear chromatin. Intranuclear eosinophilic cytoplasmic pseudo-inclusions seen within the bizarre nuclei.  Reactive to p16 (86.5%) & p53(60%). Nearly half show over 10% positive for Ki-67. Therefore; these have a limited role in distinguishing these two tumors LBN LMS Bizarre cells distributed either focally or multifocally lying in a background of smooth muscle cells of usual type background cells are usually all cytologically atypical when scrutinized at high power magnification Hypercellular Hypercellular No increase in mitosis. Degenerative changes seen within atypical nuclei. Karyorrhectic nuclei seen Increased mitosis seen Infarct type necrosis may be seen Tumor necrosis seen
  • 33. Leiomyoma with bizarre nuclei Leiomyosarcoma, background cells all pleomorphic with multinucleated bizarre cells with several mitotic figures
  • 34. FH- Deficient Leiomyoma  Leiomyomata associated with a mutation of Fumarate hydratase (FH)- overlapping features with leiomyoma with bizarre nuclei  seen in younger women <40 years of age as multiple leiomyomata  Mostly sporadic- may carry a germline mutation of FH associated with the HLRCC (hereditary leiomyomatosis and renal cell carcinoma syndrome)  . FH & S-(2-succino)-cysteine (2SC) can be detected immunohistochemically
  • 35. Show increased cellularity, staghorn vessels, neurilemmoma-like nuclear palisading and prominent inclusion-like eosinophilic macronucleoli with a perinuclear halo. Nuclear atypia and multinucleation Neurilemmoma like areas of nuclear palisading FH deficient leiomyoma with perinuclear haloes and eosinophilic inclusions
  • 36. Ddx- Smooth Muscle tumor of Uncertain Malignant Potential (STUMP) • Few tumors have phenotypic features between the benign variants and the leiomyosarcomas. • When the problem of classifying tumors with intermediate morphologic features was appreciated, a new diagnostic category was introduced—STUMP
  • 37. Epithelioid Leiomyosarcoma  Rounded, nonspindled tumor cells with abundant eosinophilic cytoplasm  May have reduced expression of smooth muscle markers (e.g., desmin, h-caldesmon). application of another marker of smooth muscle differentiation, histone deacetylase 8 (HDAC8), may be helpful
  • 38. Epithelioid Leiomyosarcoma Epithelioid Leiomyoma Epithelioid Leiomyosarcoma
  • 39. Differential Diagnosis of Epithelioid Leiomyosarcoma  Epithelioid leiomyoma  Epithelioid ESS  Perivascular Epithelioid Cell Tumor (PEComa)  Other Sarcomas with epithelioid/ rhabdoid morphology
  • 40. Ddx- Perivascular Epithelioid Cell Tumor (PEComa)  These are rare mesenchymal tumors of the FGT, MC- affecting the uterus  Characteristically they co-express melanocytic and muscle markers  Important to dx- respond to mTOR inhibitor therapy  Characterised predominantly by epithelioid, clear cell morphology and without pleomorphism and an IHC  positivity: HMB45, TFE3 and cathepsin K  negativity for MiTF, SMA and desmin
  • 41. (a) PEComa cords of cells with clear cytoplasm. (b) PEComa with immunopositivity for HMB45. (c) PEComa showing positive immmunoreactivity for TFE3
  • 42. Myxoid Leiomyosarcoma  Rare variant of uterine leiomyosarcoma  The increased extracellular matrix reduces cellularity and consequently counts of mitotic activity.  Myxoid leiomyosarcoma diagnosed with any one of the following features: (1) more than 2 mitoses/10 hpf; (2) significant cytologic atypia; (3) tumor cell necrosis; and (4) destructive infiltration of adjacent myometrium
  • 43. Myxoid Leiomyosarcoma Infiltrating tumor cells permeating through myometrial fascicles loose collection of atypical cells and an occasional mitotic figure (center and inset) in a rarified stroma.
  • 44. Differential diagnosis of Myxoid Leiomyosarcoma  Inflammatory Myofibroblastic Tumor (IMT)  Hydropic leiomyoma  Myxoid ESS
  • 45. Ddx- Inflammatory Myofibroblastic Tumor (IMT)  mesenchymal tumor of low malignant potential. It shows a cellular proliferation of spindled to epithelioid cells in a myxoid stromal background.  a conspicuous lymphoplasmacytic infiltrate within the neoplasm  Absence of IHC anaplastic lymphoma kinase (ALK) staining or ALK gene rearrangement by FISH IMT Myxoid leiomyosarcoma No evidence of aberrant immunoreactivity with p53 50% showed aberrant expression of p53, the most common being a “null” pattern Patchy, heterogenous reactivity with P16. Abnormal P16 (strong and diffuse) observed in 70% Inflammatory myofibroblastic tumor: myxoid stromal background
  • 46. Ddx- Hydropic leiomyoma • Grossly, the wet, slippery, cut surface can be described as “myxoid”. Histologically examined to exclude a myxoid leiomyosarcoma by recognizing their edematous nature and lack of other malignant features • Hydropic degeneration may be worrisome at lower magnifications- irregular contours and sharper borders • Careful attention at higher magnifications often resolves this by noting the fluid-filled intercellular spaces and the absence of truly necrotic cells.
  • 47. Immunohistochemistry in Smooth muscle tumor Marker Leiomyoma Leiomyosarcoma Desmin; h-caldesmon; smooth muscle actin histone deacetylase 8 (HDCA8) Positive; h- caldesmon- m.spec Epithelioid variant: -ve or focally reactive usually express; epithelioid and myxoid leiomyosarcomas may show lesser degrees of immunoreaction oxytocin receptor, estrogen receptor (ER), progesterone receptor(PR), and WT1 Often positive; Oxytocin receptor helps to distinguish a smooth muscle tumor (positive) from an endometrial stromal tumor (negative) ER, PR, and AR in 30-40% of cases CD10,9 cytokeratins and EMA CD10 in 40% of cellular leiomyomas often immunoreactive(EMA most frequently positive in the epithelioid variant) P16; p53; Ki67 Ki67 lower; no overexpression p53& p16 except LBN Ki67 higher; overexpression of p53(25-47%) and p16
  • 48. Mixed epithelial and mesenchymal tumors  Adenomyoma  Atypical polypoid adenomyoma  Adenofibroma  Adenosarcoma  Carcinosarcoma
  • 49. Mixed epithelial and mesenchymal tumors Atypical polypoid adenomyoma. Shown is an admixture of fibromyomatous stroma with endometrial-type glands Adenosarcoma. Note the phyllodes-like glandular growth pattern, with prominent hypercellular stroma cuffing the glands. HP: stromal cellular atypia
  • 50. Mixed epithelial and mesenchymal tumors Carcinosarcoma. Note the sharply demarcated sarcomatous region with malignant cartilage (bottom) contrasting with the
  • 52. REFFERANCES  2014 WHO Tumors of the female genital tract  Blaustein’s Pathology pf the female genital tract; 7th edition  Problematic areas and new developments in uterine mesenchymal tumors; Nafisa Wilkinson & Nicholas R Griffin; diag histopath; 2017  Diagnostic use of immunohistochemistry in uterine mesenchymal tumors; Emanuela et al; seminars in diag path; 2014  Recent developments in uterine mesenchymal neoplasms; Sarah Chiang & Esther Oliva; histopath; 2013
  • 53. REFFERANCES  Uterine mesenchymal tumors; Nikhil A. Sangle, Subodh M. Lele1; IJPM; 2011  Malignant mesenchymal tumors of the uterus - time to advocate a genetic classification; Birgit et al; Expert Review of Anticancer Therapy; 2016

Editor's Notes

  • #7: Gross feature of the benign variants of leiomyoma
  • #9: Although gross features affect the level of suspicion for malignancy, malignancy is solely determined by histologic examination
  • #22: Usual spindle cell leiomyoma- fascicles of spindle cells- elongated, “cigar” shaped nuclei- eosinophilic cytoplasm …Typically no mitoses; No cytologic atypia or coagulative tumor cell necrosis.
  • #26: metaphases with more than one spindle axis anaphases in which individual chromosomes lag far behind their companions as they are drawn to the pole of their spindle apparatus